Cargando…

Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort

Cytokine autoantibodies, particularly those directed to type I interferon (T1IFN), have been reported to portend an increased risk of severe COVID-19. Since SLE is one of the conditions historically associated with T1IFN autoantibodies, we sought to determine the prevalence of cytokine autoantibodie...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, May Y, Clarke, Ann Elaine, Buhler, Katherine, Jung, Michelle, Mathew, Hannah, Zhang, Meifeng, Cardwell, Francesca S, Waldhauser, Heather, Fritzler, Marvin J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990260/
https://www.ncbi.nlm.nih.gov/pubmed/35393285
http://dx.doi.org/10.1136/lupus-2022-000667
_version_ 1784683341016989696
author Choi, May Y
Clarke, Ann Elaine
Buhler, Katherine
Jung, Michelle
Mathew, Hannah
Zhang, Meifeng
Cardwell, Francesca S
Waldhauser, Heather
Fritzler, Marvin J
author_facet Choi, May Y
Clarke, Ann Elaine
Buhler, Katherine
Jung, Michelle
Mathew, Hannah
Zhang, Meifeng
Cardwell, Francesca S
Waldhauser, Heather
Fritzler, Marvin J
author_sort Choi, May Y
collection PubMed
description Cytokine autoantibodies, particularly those directed to type I interferon (T1IFN), have been reported to portend an increased risk of severe COVID-19. Since SLE is one of the conditions historically associated with T1IFN autoantibodies, we sought to determine the prevalence of cytokine autoantibodies in our local cohort of 173 patients with SLE prepandemic and intrapandemic, of which nine had confirmed exposure to SARS-CoV-2. Autoantibodies to 16 different cytokines, including T1IFN, were measured by an addressable laser bead immunoassay. None of the 9 patients with confirmed exposure to SARS-CoV-2 had autoantibodies to T1IFN and none had severe COVID-19 symptoms, necessitating hospitalisation. Hence, we could not confirm that TIIFN autoantibodies increase the risk for severe COVID-19. In addition, the cytokine autoantibody pattern did not differ between those with and without evidence of SARS-CoV-2 exposure.
format Online
Article
Text
id pubmed-8990260
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89902602022-04-11 Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort Choi, May Y Clarke, Ann Elaine Buhler, Katherine Jung, Michelle Mathew, Hannah Zhang, Meifeng Cardwell, Francesca S Waldhauser, Heather Fritzler, Marvin J Lupus Sci Med Brief Communication Cytokine autoantibodies, particularly those directed to type I interferon (T1IFN), have been reported to portend an increased risk of severe COVID-19. Since SLE is one of the conditions historically associated with T1IFN autoantibodies, we sought to determine the prevalence of cytokine autoantibodies in our local cohort of 173 patients with SLE prepandemic and intrapandemic, of which nine had confirmed exposure to SARS-CoV-2. Autoantibodies to 16 different cytokines, including T1IFN, were measured by an addressable laser bead immunoassay. None of the 9 patients with confirmed exposure to SARS-CoV-2 had autoantibodies to T1IFN and none had severe COVID-19 symptoms, necessitating hospitalisation. Hence, we could not confirm that TIIFN autoantibodies increase the risk for severe COVID-19. In addition, the cytokine autoantibody pattern did not differ between those with and without evidence of SARS-CoV-2 exposure. BMJ Publishing Group 2022-04-06 /pmc/articles/PMC8990260/ /pubmed/35393285 http://dx.doi.org/10.1136/lupus-2022-000667 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Brief Communication
Choi, May Y
Clarke, Ann Elaine
Buhler, Katherine
Jung, Michelle
Mathew, Hannah
Zhang, Meifeng
Cardwell, Francesca S
Waldhauser, Heather
Fritzler, Marvin J
Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
title Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
title_full Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
title_fullStr Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
title_full_unstemmed Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
title_short Cytokine autoantibodies in SARS-CoV-2 prepandemic and intrapandemic samples from an SLE cohort
title_sort cytokine autoantibodies in sars-cov-2 prepandemic and intrapandemic samples from an sle cohort
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990260/
https://www.ncbi.nlm.nih.gov/pubmed/35393285
http://dx.doi.org/10.1136/lupus-2022-000667
work_keys_str_mv AT choimayy cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT clarkeannelaine cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT buhlerkatherine cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT jungmichelle cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT mathewhannah cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT zhangmeifeng cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT cardwellfrancescas cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT waldhauserheather cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort
AT fritzlermarvinj cytokineautoantibodiesinsarscov2prepandemicandintrapandemicsamplesfromanslecohort